Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Huan Meng, Ph.D.
Huan Meng, Ph.D.

Affiliation(s):

Adjunct Assistant Professor, Department of Medicine, NanoMedicine
Member, JCCC Cancer Nanotechnology Program Area

Contact Information:

Phone:
(310) 983-3359
Email:

Scientific Interest(s):

Dr. Huan Meng’s research mainly focuses on nanomedicine and nanobiology. Meng has a broad background in pharmaceutical science and nanochemistry, with intensive experiences in cancer nanotherapy. This includes the safe design of multifunctional nanotherapeutic systems, such as mesoporous silica nanoparticles, carbonaceous nanoplatforms and liposomes for delivery/therapy/diagnosis purposes in various cancer types (e.g., breast, cervical and pancreatic cancer). He and his colleagues have developed a list of biologically functional particle design features that could successfully improve the utility of the nanotherapeutic platforms by controlling particle size, colloidal stability, charge, surface modification and aspect ratio, as well as on-demand release profile via nanovalves. Meng is also involved in the development of novel nanomedicine in infection disease.

Equally important, Meng works for the Center for Environmental Implications of Nanotechnology (CEIN) at UCLA. In CEIN, he studies the safety of engineered nanomaterials and nanobiology. Meng has successfully leveraged the knowledge in nanosafety projects to design safe nanomedicine for therapeutic purposes. In the collaboration with UCLA clinical oncologists, the long-term goal of Meng’s research is to move his platforms into the next stage of development (i.e., nanomedicine clinical trials).

Selected Cancer-Related Publications:

Meng H, Zhao Y, Dong J, Xue M, Lin YS, Ji Z, Mai WX, Zhang H, Chang CH, Brinker CJ, Zink JI, Nel AE. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano. 2013 Nov 26;7(11):10048-65. doi: 10.1021/nn404083m. Epub 2013 Oct 28.

Meng H, Mai WX, Zhang H, Xue M, Xia T, Lin S, Wang X, Zhao Y, Ji Z, Zink JI, Nel AE. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano. 2013 Feb 26;7(2):994-1005. doi: 10.1021/nn3044066. Epub 2013 Jan 4.

Mai WX, Meng H. Mesoporous silica nanoparticles: A multifunctional nano therapeutic system. Integr Biol (Camb). 2013 Jan;5(1):19-28. doi: 10.1039/c2ib20137b.

Meng H, Xue M, Xia T, Zhao YL, Tamanoi F, Stoddart JF, Zink JI, Nel AE. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J Am Chem Soc. 2010 Sep 15;132(36):12690-7.

Liang XJ, Meng H, Wang Y, He H, Meng J, Lu J, Wang PC, Zhao Y, Gao X, Sun B, Chen C, Xing G, Shen D, Gottesman MM, Wu Y, Yin JJ, Jia L. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7449-54. doi: 10.1073/pnas.0909707107. Epub 2010 Apr 5.